Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Non-Current Liabilities: 2019-2025

Historic Other Non-Current Liabilities for Revolution Medicines (RVMD) over the last 6 years, with Sep 2025 value amounting to $5.9 million.

  • Revolution Medicines' Other Non-Current Liabilities rose 114.19% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 114.19%. This contributed to the annual value of $3.2 million for FY2024, which is 51.03% down from last year.
  • As of Q3 2025, Revolution Medicines' Other Non-Current Liabilities stood at $5.9 million, which was down 17.85% from $7.2 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Other Non-Current Liabilities ranged from a high of $7.2 million in Q2 2025 and a low of $219,000 during Q2 2022.
  • For the 3-year period, Revolution Medicines' Other Non-Current Liabilities averaged around $3.4 million, with its median value being $3.2 million (2024).
  • As far as peak fluctuations go, Revolution Medicines' Other Non-Current Liabilities crashed by 63.98% in 2022, and later skyrocketed by 2,063.46% in 2023.
  • Over the past 5 years, Revolution Medicines' Other Non-Current Liabilities (Quarterly) stood at $634,000 in 2021, then plummeted by 52.52% to $301,000 in 2022, then surged by 2,063.46% to $6.5 million in 2023, then slumped by 51.03% to $3.2 million in 2024, then surged by 114.19% to $5.9 million in 2025.
  • Its Other Non-Current Liabilities stands at $5.9 million for Q3 2025, versus $7.2 million for Q2 2025 and $4.1 million for Q1 2025.